List of Figures

FIGURE 1 VACCINES MARKET SEGMENTATION 19
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 24
FIGURE 4 BOTTOM-UP APPROACH 25
FIGURE 5 TOP-DOWN APPROACH 25
FIGURE 6 DATA TRIANGULATION METHODOLOGY 26
FIGURE 7 VACCINES MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION) 28
FIGURE 8 VACCINES MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION) 29
FIGURE 9 VACCINES MARKET, BY DISEASE INDICATION, 2019 VS. 2024 (USD MILLION) 29
FIGURE 10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2019 VS. 2024 (USD MILLION) 30
FIGURE 11 VACCINES MARKET, BY PATIENT TYPE, 2019 VS. 2024 (USD MILLION) 30
FIGURE 12 VACCINES MARKET: GEOGRAPHICAL SNAPSHOT 31
FIGURE 13 HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH 32
FIGURE 14 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VACCINES MARKET IN 2018 33
FIGURE 15 ASIA TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET
FROM 2019 TO 2024 34
FIGURE 16 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 17 REGULATORY APPROVAL PROCESS FOR VACCINES 42
FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2024 95
FIGURE 19 NORTH AMERICA: VACCINES MARKET SNAPSHOT 96
FIGURE 20 EUROPE: VACCINES MARKET SNAPSHOT 103
FIGURE 21 ASIA: VACCINES MARKET SNAPSHOT 112
FIGURE 22 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 125
FIGURE 23 COMPETITIVE LEADERSHIP MAPPING: VACCINES MARKET (2018) 128
FIGURE 24 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT (2018) 132
FIGURE 25 MERCK & CO., INC.: COMPANY SNAPSHOT (2018) 136
FIGURE 26 PFIZER, INC.: COMPANY SNAPSHOT (2018) 139
FIGURE 27 SANOFI PASTEUR SA: COMPANY SNAPSHOT (2018) 143
FIGURE 28 CSL LIMITED: COMPANY SNAPSHOT (2018) 148
FIGURE 29 EMERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2018) 151
FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018) 154
FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2018) 157
FIGURE 32 BAVARIAN NORDIC: COMPANY SNAPSHOT (2018) 162
FIGURE 33 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2018) 165
FIGURE 34 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2018) 167
FIGURE 35 PANACEA BIOTEC: COMPANY SNAPSHOT (2018) 169

 

List of Tables

TABLE 1 INCIDENCE OF INFECTIOUS DISEASES 36
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2014–2020 (USD MILLION) 37
TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2016 VS. 2018 40
TABLE 4 REGULATORY AUTHORITIES IN EUROPE 43
TABLE 5 REGULATORY AUTHORITIES IN ASIA 44
TABLE 6 KEY PIPELINE VACCINES 45
TABLE 7 VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 57
TABLE 8 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR PEDIATRIC PATIENTS 58
TABLE 9 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR ADULT PATIENTS 58
TABLE 10 CONJUGATE VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 58
TABLE 11 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 60
TABLE 12 INACTIVATED & SUBUNIT VACCINES MARKET, BY REGION 2017–2024 (USD MILLION) 60
TABLE 13 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 14 EXAMPLES OF RECOMBINANT VACCINES 62
TABLE 15 RECOMBINANT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 62
TABLE 16 TOXOID VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 17 VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 65
TABLE 18 MONOVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 66
TABLE 19 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 67
TABLE 20 MULTIVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 21 VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 69
TABLE 22 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 70
TABLE 23 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION 2017–2024 (USD MILLION) 71
TABLE 24 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 72
TABLE 25 INFLUENZA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 72
TABLE 26 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 73
TABLE 27 DTP VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 74
TABLE 28 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 75
TABLE 29 HPV VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 75
TABLE 30 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
IN THE MARKET 76
TABLE 31 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION 2017–2024 (USD MILLION) 76
TABLE 32 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 77
TABLE 33 HEPATITIS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 78
TABLE 34 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 79
TABLE 35 POLIO VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 79
TABLE 36 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 80
TABLE 37 ROTAVIRUS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 80
TABLE 38 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 81
TABLE 39 MMR VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 81
TABLE 40 HERPES ZOSTER VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 82
TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 83
TABLE 42 VARICELLA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 83
TABLE 43 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 84
TABLE 44 OTHER DISEASE INDICATION VACCINES MARKET, BY REGION 2017–2024 (USD MILLION) 84
TABLE 45 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION) 86
TABLE 46 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 87
TABLE 47 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION) 87
TABLE 48 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION 2017–2024 (USD MILLION) 88
TABLE 49 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION 2017–2024 (USD MILLION) 89
TABLE 50 VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 91
TABLE 51 VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION 2017–2024 (USD MILLION) 92
TABLE 52 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2017–2024 (USD MILLION) 92
TABLE 53 VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2017–2024 (USD MILLION) 93
TABLE 54 NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY 2017–2024 (USD MILLION) 93
TABLE 55 VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 95
TABLE 56 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 97
TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 97
TABLE 58 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 59 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION 2017–2024 (USD MILLION) 98
TABLE 60 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 98
TABLE 61 NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE 2017–2024 (USD MILLION) 98
TABLE 62 NUMBER OF NEW INFECTIOUS DISEASE CASES IN THE US, 2017 99
TABLE 63 US: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 100
TABLE 64 US: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 100
TABLE 65 NUMBER OF NEW INFECTIOUS DISEASE CASES IN CANADA, 2015–2017 101
TABLE 66 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 101
TABLE 67 CANADA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 101
TABLE 68 EUROPE: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 104
TABLE 69 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 104
TABLE 70 EUROPE: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 71 EUROPE: VACCINES MARKET, BY DISEASE INDICATION 2017–2024 (USD MILLION) 105
TABLE 72 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 105
TABLE 73 EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 105
TABLE 74 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 106
TABLE 75 UK: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 107
TABLE 76 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 108
TABLE 77 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 109
TABLE 78 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 110
TABLE 79 ROE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 111
TABLE 80 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY 2000 VS. 2014 VS. 2016 (USD) 111
TABLE 81 ASIA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 113
TABLE 82 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 113
TABLE 83 ASIA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 113
TABLE 84 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 114
TABLE 85 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 114
TABLE 86 ASIA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 114
TABLE 87 DISEASE INCIDENCE IN JAPAN, 2016–2018 115
TABLE 88 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 115
TABLE 89 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 116
TABLE 90 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 117
TABLE 91 ROA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 118
TABLE 92 ROW: VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 118
TABLE 93 ROW: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 118
TABLE 94 ROW: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 95 ROW: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 119
TABLE 96 ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 119
TABLE 97 ROW: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 120
TABLE 98 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 121
TABLE 99 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 100 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION 2017–2024 (USD MILLION) 121
TABLE 101 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION 2017–2024 (USD MILLION) 122
TABLE 102 LATIN AMERICA: VACCINES MARKET, BY PATIENT TYPE 2017–2024 (USD MILLION) 122
TABLE 103 OTHER ROW COUNTRIES: VACCINES MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 123
TABLE 104 OTHER ROW COUNTRIES: VACCINES MARKET, BY TYPE 2017–2024 (USD MILLION) 123
TABLE 105 OTHER ROW COUNTRIES: VACCINES MARKET, BY DISEASE INDICATION 2017–2024 (USD MILLION) 124
TABLE 106 OTHER ROW COUNTRIES: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION) 124
TABLE 107 OTHER ROW COUNTRIES: VACCINES MARKET, BY PATIENT TYPE 2017–2024 (USD MILLION) 124